Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Hemostemix Inc (HEM)

TSXV
Symbol
Exchange
Currency
HEMTSXVCAD
HEMCBOE CanadaCAD
Currency in CAD
Disclaimer
0.0400
0.0000(0.00%)
Delayed Data

HEM Comments

$HEM's focus on autologous cell therapies holds immense potential for revolutionizing healthcare. Exciting to see the impact they can make over TSX-V by attracting long term investors.
With a market cap exceeding $3.9M and over 87.12M outstanding shares, Hemostemix ( $HEM ) presents an intriguing investment opportunity in the rapidly evolving field of regenerative medicine.
With an impressive market cap and 87.12 million outstanding shares, $HEM holds a prominent position as the most valuable penny stock on the TSXV index.
$HEM shines brightly as a good performer on the TSX-V index! With a trading price of $0.04 and significant trading volume, $HEM's outstanding performance is driving excitement and interest in the stock market.
Recent trading volumes surged to 111K, indicating a rising investor interest in $HEM activities and projects.
Despite an initial open of $0.05, the stock's 52-week high of $0.175 signifies considerable upside potential. With a market cap of $4.35M, Hemostemix ($HEM) operates within the smaller biotech landscape.
With 87.12 million outstanding shares, $HEM possesses a sizable equity base.
$HEM showcases both volatility in the biotech arena, its 52-week high/low range of $0.175/$0.05 highlights the significant gains.
$HEM average volume of 33.15k shares, it seems like investors are sticking around for the long haul, believing in the company's vision.
$HEM sustains investor interest, opening at $0.055 with a 20-day average volume of 30.25k shares.
Over the past 30 days, $HEM has emerged as a beacon of innovation, drawing the attention of investors with its pioneering work in stem cell therapies. With an average daily trading volume of 28.23K shares, the stock reflects growing investor interest in the company's potential to revolutionize healthcare.
At its current trading price of $0.055, $HEM stock reflects both the challenges and opportunities inherent in the dynamic realm of stem cell therapies. The 52-week range, spanning from a low of $0.05 to a high of $0.175, underscores the volatility that characterizes investments in this sector.
market cap of $4.79M and outstanding shares of 87.12M, $HEM's potential for growth is evident, albeit with some volatility.
$HEM is priced at $0.055, with a market cap of $4.79M and outstanding shares of 87.12M. Volume stands at 65.02k, showing investor interest.
$HEM remains a trusted asset, buoyed by a 50-day moving average of $0.076. Investors remain keenly attuned to the company's trajectory.
Despite modest trading volume averaging 31.35K shares over 30 days, $HEM is making significant strides in the development of blood-derived cell therapies. Quality over quantity in healthcare innovation.
$HEM commands a market capitalization of $5.23 million, with an impressive 87.12 million outstanding shares. Despite a 52-week high/low of $0.175/$0.05, the stock's 21-day moving average is holding steady at $0.067.
$HEM navigates market fluctuations with outstanding shares of 87.12M. Despite volatility, the company's 52-week high/low of $0.175/$0.05.
$HEM's market cap remains steady at $5.23M, showcasing the company's resilience amidst market dynamics.
Volatility is no match for $HEM, which stands strong with its 52-week high/low of $0.175/$0.05.
This company's financial support is disappointing, the management team is not good, this company is not long-term, and overall, this company is fraudulent.
Hemostemix Inc. ($HEM): The company's primary technology platform is designed to isolate and expand blood-derived cells, including stem cells and immune cells, for use in cell therapy products. The stock $HEM is trading with a market cap of $12 million or more on the TSX-V.
Hemostemix Inc.'s ($HEM) recognition with the World Economic Forum Technologies Pioneer Award further highlights its innovative approach and potential for growth. With a current market cap of $12,163,444, Hemostemix may be a compelling investment opportunity for those interested in the regenerative medicine sector.
Hemostemix Inc. ($HEM) is paving the way for innovative treatments, including sickle cell disease with 81,089,626 shares listed on TSXV, today's trading price at $0.140, this could be your chance for funding in the future of healthcare.
If you're looking for a stock with serious growth potential, $HEM is the one for you. With a closing price of just 0.14, this autologous stem cell therapy stock is a steal for savvy investors.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.